On the origins of tumor mutations in cancer genes: Insights from the p53 gene

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 405, Issue 2, 1998, Pages 145-154

  Hollstein, Monica ^a   Moeckel, Gerd ^b   Hergenhahn, Manfred ^a   Spiegelhalder, Bertold ^a   Keil, Matthias ^b   Werle Schneider, Gisela ^a   Bartsch, Helmut ^a   Brickmann, Jürgen ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Mutation spectrum; p53 Gene; Somatic mutation

Indexed keywords

AFLATOXIN B1; AROMATIC AMINE; CYCLOPHOSPHAMIDE; DYE; INDUSTRIAL CHEMICAL; MUTAGENIC AGENT; PROTEIN P53; TOBACCO SMOKE;

CANCER RISK; CARCINOGENESIS; CONFERENCE PAPER; GENE MUTATION; HIGH RISK POPULATION; HUMAN; MUTATION RATE; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; TANDEM REPEAT; TUMOR SUPPRESSOR GENE;

CARCINOGENS; GENES, P53; HUMANS; MUTAGENESIS; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

NICOTIANA TABACUM;

EID: 0002881327     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(98)00131-6     Document Type: Conference Paper

References (46)

1. [1] M. Hollstein, B. Shomer, M. Greenblatt et al., Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation, Nucl. Acids Res. 24 (1996) 141-146.
2. [2] P. Hainaut, T. Soussi, B. Shomer, M. Hollstein, M. Greenblatt, E. Hovig, C.C. Harris, R. Montesano, Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects, Nucl. Acids Res. 25 (1997) 151-157.
3. [3] D. Sidransky, M. Hollstein, Clinical implications of the p53 gene, Annu. Rev. Med. 47 (1996) 285-301.
4. [4] T. Lindahl, Instability and decay of the primary structure of DNA, Nature 362 (1993) 709-715.
5. [5] D.N. Cooper, M. Youssoufian, The CpG dinucleotide and human genetic disease, Hum. Genet. 78 (1988) 151-158.
6. [6] B.N. Ames, M.K. Shigenaga, T.M. Hagen, Oxidants, antioxidants, and the degenerative diseases of aging, Proc. Natl. Acad. Sci. USA 90 (1993) 7915-7922.
7. [7] W. Xiao, L. Samson, In vivo evidence for endogenous DNA alkylation damage as a source of spontaneous mutation in eukaryotic cells, Proc. Natl. Acad. Sci. USA 90 (1993) 2117-2121.
8. [8] B.S. Strauss, Commentary: silent and multiple mutations in p53 and the question of the hypermutability of tumors, Carcinogenesis 18 (1997) 1445-1452.
9. [9] B. Richards, H. Zhang, G. Phear, M. Meuth, Conditional mutator phenotypes in hMSH2-deficient tumor cell lines, Science 277 (1997) 1523-1526.
10. [10] J. Cairns, J. Overbaugh, S. Miller, The origin of mutants, Nature 335 (1988) 142-145.
11. [11] E.F. Mao, L. Lane, J. Lee, J.H. Miller, Proliferation of mutators in a cell population, J. Bacteriol. 179 (1997) 417-422.
12. [12] Z.-P. Ren, A. Ahmadian, F. Pontén et al., Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin, Am. J. Pathol. 150 (1997) 1791-1803.
13. [13] A.S. Jonason, S. Kunala, G.J. Price, Frequent clones of p53-mutated keratinocytes in normal skin, Proc. Natl. Acad. Sci. USA 93 (1996) 14025-14029.
14. [14] H. Nakazawa, D. English, P.L. Randell et al., UV and skin cancer: specific p53 gene mutations in normal skin as a biologically relevant exposure measurement, Proc. Natl. Acad. Sci. USA 91 (1994) 360-364.
15. [15] A. Ziegler, A.S. Jonason, D.J. Leffell et al., Sunburn and p53 in the onset of skin cancer, Nature (London) 372 (1994) 773-776.
16. [16] M.S. Greenblatt, W.P. Bennett, M. Hollstein, C.C. Harris, Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis, Cancer Res. 54 (1994) 4855-4878.
17. [17] D. Malkin, Germline p53 mutations and heritable cancer, Annu. Rev. Genet. 28 (1994) 443-465.
18. [18] R. Peto, Epidemiology, multistage models and short-term mutagenicity tests, in: H.H. Hiatt et al. (Eds.), Origins of Human Cancer, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1977, pp. 1403-1428.
19. [19] J. Cairns, The origin of human cancers, Nature 289 (1981) 353-357.
20. [20] J. Cairns, Mutation and cancer: the antecedents to our studies of adaptive mutation, Genetics, in press.
21. [21] J.A. Brennan, J.O. Boyle, W.M. Koch et al., Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck, New Engl. J. Med. 332 (1995) 712-717.
22. [22] Y. Takeshima, T. Seyama, W.P. Bennett et al., p53 Mutations in lung cancers from non-smoking atomic-bomb survivors, Lancet 342 (1993) 1520-1521.
23. [23] R. Montesano, M. Hollstein, P. Hainaut, Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis, Int. J. Cancer 69 (1996) 225-235.
24. [24] P. Kleihues, B. Schaeuble, A. zur Hausen et al., Tumors associated with p53 germline mutations. A synopsis of 91 families, Am. J. Pathol. 150 (1997) 1-13.
25. [25] R. Montesano, G.M. Kirby, Chemical carcinogens in human liver cancer, in: C. Brechot (Ed.), Primary Liver Cancer: Etiological and Progression Factors, CRC, Boca Raton, EL, 1994, pp. 55-77.
26. [26] M.A. Khan, L.B. Travis, C.F. Lynch, et al., p53 Mutations in cyclophosphamide-associated bladder cancers, Cancer Epidemiology, Biomarkers, Prevention, in press.
27. [27] A. Esteve, T. Sorle, G. Martel-Planche et al., Screening for p53 gene mutations in archived tumors of workers occupationally exposed to carcinogens: examples from analysis of bladder tumors, J. Occup. Environ. Health 37 (1995) 59-68.
28. [28] J.A. Taylor, Y. Li, M. He et al., Mutations in bladder tumors from arylamine-exposed workers, Cancer Res. 56 (1996) 294-298.
29. [29] W. Warren, P.J. Biggs, M. El-Baz, Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours, Carcinogenesis 16 (1995) 1181-1189.
30. [30] B. Vogelstein, K.W. Kinzler, p53 Function and dysfunction, Cell 70 (1992) 523-526.
31. [31] K.W. Kinzler, B. Vogelstein, Gatekeepers and caretakers, Nature 386 (1997) 761-762.
32. [32] A.J. Levine, p53, The cellular gatekeeper for growth and division, Cell 89 (1997) 323-331.
33. [33] Y. Cho, S. Gorina, P.D. Jeffrey, N.P. Pavletich, Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations, Science 265 (1994) 346-355.
34. [34] C. Prives, How loops, beta sheets, and alpha helices help us to understand p53, Cell 78 (1994) 543-546.
35. [35] N.F. Cariello, W.W. Piegorsch, W.T. Adams, T.R. Skopek, Computer program for the analysis of mutational spectra: application to p53 mutations, Carcinogenesis 15 (1994) 2281-2285.
36. [36] C. Coulondre, J.H. Miller, Genetic studies of the lac represser: IV. Mutagenic specificity in the Lad gene of E. coli, J. Mol. Biol. 117 (1977) 577-606.
37. [37] I. Mellon, G. Spivak, P.C. Hanawalt, Selective removal of transcription-blocking DNA damage from the transcribed strand of the mammalian DHFR gene, Cell 51 (1987) 241-249.
38. [38] R.H. Chen, V.M. Maher, J.J. McCormick, Effect of excision repair by diploid human fibroblasts on the kinds and locations of mutations induced by (+ / -)-7beta,8alpha-dihydroxy-9alpha,1alpha-epoxy-7,8,9,10-tetrahydrobenzo(a)-pyrene in the coding region of the HPRT gene, Proc. Natl. Acad. Sci. USA 87 (1990) 8680-8684.
39. [39] R.E. Wellinger, F. Thoma, Nucleosome structure and positioning modulate nucleotide excision repair in the non-transcribed strand of an active gene, EMBO J. 16 (1997) 5046-5056.
40. [40] M.F. Denissenko, A. Pao, M.-S. Tang, G.P. Pfeifer, Preferential formation of benzo(a)pyrene adducts at lung cancer mutational hotspots in p53, Science 274 (1996) 430-432.
41. [41] S. Friend, p53: a glimpse at the puppet behind the shadow play, Science 265 (1994) 334-335.
42. [42] G. Moeckel, M. Keil, M. Hollstein, B. Spiegelhalder, H. Bartsch, J. Brickmann, VRML in cancer research. Local changes in binding properties of wild type and mutated p53 tumor suppressor protein, J. Mol. Model. 3 (1997) 382-385.
43. [43] J. Brickmann, T. Goetze, W. Heiden, G. Moeckel, S. Reiling, H. Volhard, C.-D. Zachmann, in: J. Bowie (Ed.), Interactive Visualization of Molecular Scenarios with MOLCAD/ SYBYL in Data Visualization in Molecular Science: Tools for Insight and Innovation, Addison-Wesley Publishing, Reading, MA, 1995, pp. 83-97.
44. [44] L. Loeb, Mutator phenotype may be required for multistage carcinogenesis, Cancer Res. 51 (1991) 3075-3079.
45. [45] S.J. Baker, E.R. Fearon, J.M. Nigro et al., Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas, Science 244 (1989) 217-221.
46. [46] G.P. Holmquist, S. Gao, Somatic mutation theory, DNA repair rates, and the molecular epidemiology of p53 mutations, Mutat. Res. 386 (1997) 69-101.